Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Discovery
Filter
Filter
Sort By
Newest First
1 / 45
Sector
Modality / Product
Reset
Clinical Trials
New SELECT trial analysis with semaglutide 2.4 mg showed a reduction in hospital admissions with heart disease and overweight
Novo Nordisk
PR-10-24-NI-74
Nov 05, 2024
Clinical Trials
TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with regimen in both induction and maintenance
Johnson & Johnson
PR-10-24-NI-64
Oct 28, 2024
Financing
Samsung Biologics reports third quarter 2024 financial results
Samsung Biologics
PR-10-24-NI-58
Oct 23, 2024
Biopharma
Life Sciences and Cryoport Form Partnership to Elevate Standards for Frozen Egg, Embryo, etc Offsite Storage and Biologistics
Cryoport
PR-10-24-NI-52
Oct 21, 2024
FDA
U.S. Food and Drug Administration
U.S. Food & Drug Administration
PR-10-24-NI-44
Oct 14, 2024
FDA
FDA Approves IMULDOSA, Accord BioPharma's Biosimilar to STELARA, for the Treatment of Chronic Inflammatory Conditions
Accord Biopharma
PR-10-24-NI-43
Oct 14, 2024
FDA
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
Systimmune, Inc.
PR-10-24-NI-42
Oct 14, 2024
Appointment
Prime Therapeutics bolsters its position as industry leader with 10 research studies at AMCP Nexus 2024
Prime Therapeutics
PR-10-24-NI-40
Oct 11, 2024
Financing
AMD Drugs Market to Hit USD 17.37 Billion by 2029 with 10.7% CAGR | MarketsandMarkets™
MarketsandMarkets™
PR-09-24-NI-22
Sep 27, 2024
Biopharma
Revolutionizing Autoimmune Disease Management with Soluble Bispecific Receptors
Gardiner Smith; Reiner Gentz, Ph.D.
Fab Biopharma
PR-09-24-NI-19
Sep 27, 2024
Biopharma
AbZelectPRO™ enables biopharma customers to reach their research cell bank in 10 weeks with 8g/L
Abzena
PR-09-24-NI-18
Sep 26, 2024
Biotech
Five Small Biotechs to Watch: October 2024
David Alvaro, Ph.D.
Pharma's Almanac
PR-09-24-NI-10
Sep 23, 2024
Sustainability
Piramal Pharma’s GHG Commitment Validated and Approved by SBTi
Piramal Pharma Ltd.
PR-09-24-NI-04
Sep 16, 2024
Female-Centric
Transforming Drug Development through a Female Perspective
Chia Chia Sun; William Freimuth, Ph.D., M.D.
Fab Biopharma
PAO-09-24-CL-03
Sep 10, 2024
Developability
Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform
Heonchang Lim
Samsung Biologics
PAO-09-24-CL-04
Sep 04, 2024
Minitablets
Minitablets: Enhancing Safety and Palatability for Pediatric Medicines
Gus LaBella
Mikart
PAO-09-24-CL-01
Aug 30, 2024
Drug Delivery
Nanocarriers to Overcome the Blood–Brain Barrier (BBB)
Serene Lee
Nice Insight
PAO-09-24-NI-01
Aug 30, 2024
Changing Roles
How are Advancements in Technology Reshaping the Roles and Capabilities of CDMOs and CROs in the Drug Development Life Cycle?
Pharma's Almanac
PAO-08-24-RT-01
Aug 07, 2024
Monoclonal Antibodies
Coriolis Pharma Launches U.S. Entity Alongside Innovative Drug Product Platform Service Offerings for Monoclonal Antibodies
Coriolis Pharma
PR-05-24-NI-02
Jun 18, 2024
Protein Degradation
PROTACS: Upgrading Small Molecule Inhibitors
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-06-24-NI-02
Jun 11, 2024
1 / 45
